Adamax Dosage & Reconstitution - Dosage Peptide

The central research question behind almost every search for “adamax dosage” is deceptively simple: how much of a 10mg vial does a protocol call for, and how should it be reconstituted? The honest answer is that no controlled human dose-ranging study of Adamax has ever been published, so any figure you encounter is an extrapolation from the parent Semax and ACTH(4-10) literature rather than a validated dose. This article separates the arithmetic that is reliable — reconstitution math, concentration anchors, unit conversions — from the dosing folklore that is not, so that laboratory modeling rests on what the evidence actually supports rather than on numbers copied between forums.

Research Context: What “Adamax Dosage” Actually Refers To

Adamax is a research peptide marketed as an ACTH(4-10)/melanocortin-derived neuropeptide sitting inside the same structural family as Semax, the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro. Semax itself is built from the ACTH(4-7) melanocortin core (Met-Glu-His-Phe) extended at the C-terminus with a Pro-Gly-Pro tail that blocks the carboxypeptidases that would otherwise destroy the molecule.[1] When a vendor sells a compound called “Adamax,” it is positioning that product against this well-documented Russian neuropeptide lineage. The practical consequence for anyone researching dosage is uncomfortable but important to state plainly: the name buys you a family resemblance to Semax, not a body of Adamax-specific pharmacology.

This matters because a dosage is only meaningful when it is anchored to data — a dose that produced a measured effect in a defined model at a defined concentration. For Semax and its immediate relatives, that data exists, largely from Russian laboratories and clinical groups, and it is citable. For Adamax as a distinct, separately-studied entity, it essentially does not. There is no peer-reviewed human trial titled around Adamax, no published Adamax dose-response curve, no Adamax pharmacokinetic dataset. Every “adamax dosage” number in circulation — including figures on protocol pages, this site’s included — is therefore a modeling assumption borrowed from Semax intranasal solutions (the Russian 0.1% formulation equals 1 mg/mL, the 1% formulation equals 10 mg/mL) and from community lore, not from a controlled Adamax study.

The most useful thing a genuinely honest dosage reference can do, then, is two-fold. First, teach the reconstitution and concentration arithmetic precisely, because that math is real regardless of which peptide sits in the vial: 10 mg of dry powder plus a known volume of bacteriostatic water yields a known mg/mL concentration, and that concentration converts cleanly into mcg-per-insulin-unit. Second, catalog the parent-compound evidence transparently, clearly labelled as Semax/ACTH(4-10) data and never dressed up as Adamax evidence. For orientation on how Adamax is positioned relative to its namesake, our companion explainer on what Adamax is as an ACTH neuropeptide versus Semax in research works through the naming and structural questions in depth, and the underlying Adamax 10mg vial dosage protocol page lays out the circulated figures that the sections below deliberately hold at arm’s length.

Why the vial size (10mg) is the one hard fact

Amid the uncertainty, the vial label is the single fixed quantity you can build on. Adamax is sold as a 10mg vial of lyophilized (freeze-dried) powder. That number is not a dose — it is the total mass of peptide in the container, from which many different working concentrations can be made depending on how much diluent is added. A researcher who understands that 10mg is a total, not a per-administration amount, is already ahead of most of the confusion online, where the two are routinely conflated. The entire reconstitution section of this article exists to convert that one hard fact into transparent, checkable numbers.

The search intent behind “adamax dosage”

It is worth naming what a person typing “adamax dosage” is usually trying to accomplish, because the honest answer reshapes the whole query. Most such searches want a single tidy number — “take X mcg, Y times a day.” That framing quietly assumes three things that are not true for this compound: that a validated dose exists, that the dose would be the same regardless of concentration and route, and that a general internet figure could substitute for a defined research context. None of those hold. What genuinely helps the underlying intent is not a fabricated number but a working command of the two things that are knowable: the reconstitution math that turns 10 mg of powder into a defined concentration, and the parent-compound literature that establishes the order of magnitude at which this chemical family has ever been studied. Reframed that way, “adamax dosage” becomes a question a careful researcher can actually reason about instead of a number to be copied. Everything below is organized around that reframing, and the dosage calculator exists precisely so the arithmetic never has to be guessed.

How Does Adamax Work? Mechanism via the Melanocortin/ACTH(4-10) Pathway

Because Adamax has no mechanistic literature of its own, the only defensible way to discuss how it might work is to describe the molecular pathways established for Semax and the broader ACTH(4-10) melanocortin fragments, and to be explicit that this is parent-compound reasoning. In the Semax literature, the most reproducible molecular signature is upregulation of neurotrophins. A single intranasal application of Semax at 50 µg/kg in rats produced a roughly 1.4-fold increase in brain-derived neurotrophic factor (BDNF) protein and a 1.6-fold increase in TrkB receptor tyrosine phosphorylation, alongside several-fold increases in BDNF and TrkB mRNA in the hippocampus.[2] A separate radioligand study showed Semax binds specifically to plasma membranes of the rat basal forebrain and raises BDNF protein there within about three hours.[1]

Beyond neurotrophins, Semax has been reported to modulate monoaminergic systems, raising striatal serotonin-metabolite levels and potentiating amphetamine-evoked dopamine release in rodent brain.[3] At the cellular level, application of Semax at 1 µM increased the frequency of spontaneous intracellular calcium fluctuations in hippocampal CA1 pyramidal neurons, one candidate substrate for its reported effects on neuronal signaling.[9] In models of cerebral ischemia, genome-wide transcriptional analyses have shown Semax shifting the expression of genes tied to immune and vascular function, and protein-expression profiling has documented a protective signature in ischemia–reperfusion.[4][5]

The receptor question and the melanocortin lineage

The parent ACTH(4-10) sequence descends from adrenocorticotropic hormone, and the melanocortin system (MC1R–MC5R) is its natural receptor family. A key design goal of the Semax molecule was to retain the neurotrophic and behavioral activity of ACTH(4-10) while stripping away the classical hormonal (corticotropic) effects — that is, to act on brain signaling without driving cortisol release. This is why the literature frames Semax as a “neuropeptide” rather than a hormone. The exact receptor-level accounting is still incompletely resolved even for Semax, with contributions proposed from melanocortin receptors, neurotrophin signaling, and downstream transcriptional cascades rather than a single clean receptor–ligand story. For Adamax specifically, none of this has been measured; the assumption is that a closely related sequence would engage similar machinery, but assumption is the operative word.

Active metabolites: why the story does not end at clearance

One genuinely interesting feature of the Semax family is that degradation does not simply mean inactivation. Semax is cleaved rapidly by tissue and plasma peptidases — the intact molecule is short-lived — but the sequential breakdown yields fragments such as HFPGP and ultimately the Pro-Gly-Pro (PGP) tripeptide, several of which retain their own biological activity.[10][11] The glyproline PGP tail has itself been studied for anti-inflammatory and neuroprotective activity in ischemia models.[14] This “prodrug-like” cascade is one reason short apparent half-lives do not necessarily translate into short functional effects in the parent literature — and one more reason that naively porting a plasma half-life into an Adamax dosing schedule would be speculative.

Anti-inflammatory and transcriptional effects in ischemia models

A large fraction of the strongest Semax data comes from cerebral-ischemia models, and it is transcriptional rather than receptor-binding in character. Genome-wide expression studies in rat brain focal ischemia found Semax altering the activity of gene networks tied to immune and vascular function, consistent with a broadly protective, anti-inflammatory shift rather than a single narrow target effect.[4] Complementary work has reported that Semax and its Pro-Gly-Pro fragment together activate transcription of neurotrophins and their receptor genes after ischemia, reinforcing the picture of a peptide that acts partly by nudging endogenous neurotrophic and inflammatory programs.[6] The practical dosing takeaway is subtle but important: if the mechanism is substantially about shifting gene-expression programs over hours, then a dosing model built purely around minute-scale plasma kinetics misunderstands the pharmacodynamics. This is one reason the parent literature emphasizes repeated intranasal courses rather than chasing a peak plasma concentration — and a reason any Adamax schedule inferred from first principles is on shaky ground.

What the human cognition evidence does and does not show

Because Adamax is marketed with cognitive framing, it is worth being precise about what the human ACTH(4-10) cognition literature actually demonstrates, since this is the closest thing to human data in the whole lineage. The honest summary is: modest, inconsistent, and often null or even negative. Studies of ACTH(4-10) and the MSH/ACTH(4-10) fragment on attention and short-term memory in humans stretch back decades and repeatedly failed to produce a robust, reproducible enhancement; some reported impaired electrophysiological indices of selective attention, interpreted as nonspecific arousal rather than sharpened focus.[12] Later event-related-potential work with intranasal ACTH(4-10) and desacetyl-alpha-MSH similarly found only limited, task-specific effects on working-memory measures, and in some conditions impaired recall.[13] The point for a dosage reference is that even the parent compound never yielded a clean human dose–response curve for cognition, so there is no validated cognitive target dose to inherit — a fact that should temper any confident cognitive-dosing claim about Adamax.

The Semax Family: The Only Real Evidence Base for Adamax

If Adamax is going to be discussed responsibly, the reader deserves a clear map of what the surrounding family actually consists of, because that family — not Adamax — is where every citable number lives. Three named compounds anchor the picture.

Semax (ACTH(4-7)PGP, Met-Glu-His-Phe-Pro-Gly-Pro). The most-studied member, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is registered in Russia for ischemic stroke and cognitive/circulatory indications and sold there as an intranasal solution (0.1% and 1%). It is not approved by the FDA or EMA, and Western-standard large randomized controlled trials are lacking.[8] Our Semax dosage chart covering intranasal and subcutaneous protocols collates the figures that appear in the Russian literature.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro). A tuftsin analog with the same Pro-Gly-Pro stabilizing motif, developed by the same institute, studied mainly as an anxiolytic acting through GABAergic and related pathways. A Russian comparative trial of 62 patients compared intranasal Selank at 1,350 mcg/day against the benzodiazepine medazepam and reported comparable anxiety-scale reductions.[15] Like Semax, it is a Russia-registered product only. Our overview of Selank as a nootropic peptide studied for anxiety and cognition details that evidence base.

ACTH(4-10) and its analogs. The historical parent. Human work on ACTH(4-10) and the closely related MSH/ACTH(4-10) fragment dates to the 1970s–2000s, examining effects on attention, arousal and short-term memory with mixed and often modest results — some studies even reported impaired electrophysiological signs of selective attention rather than enhancement.[12][13]

Adamax is marketed as belonging to this lineage. Whether a given vendor’s Adamax is chemically identical to Semax, a distinct ACTH(4-10) analog, or a proprietary variant is frequently unstated and unverifiable from public certificates of analysis. That ambiguity is itself a dosing problem: you cannot confidently transfer a Semax dose to Adamax if you cannot confirm the two share a sequence and molecular weight.

Semax

Met-Glu-His-Phe-Pro-Gly-Pro

Neurotrophic / neuroprotective, ischemic stroke

Registered in Russia; not FDA/EMA approved

Stroke use ~6,000–18,000 mcg/day intranasal[7]

Selank

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Anxiolytic (GABAergic)

GAD trial 1,350 mcg/day intranasal[15]

ACTH(4-10)

Met-Glu-His-Phe-Arg-Trp-Gly

Attention/memory (historical)

Never approved; investigational/historical

Human EEG/memory studies, variable doses[13]

Adamax

Marketed as ACTH(4-10)/melanocortin-derived

Research chemical; positioned in Semax family

Not approved anywhere; no monograph

None — no Adamax-specific study exists

How Researchers Reconstitute a 10mg Adamax Vial

This is the part of the “adamax dosage” question where the numbers are genuinely trustworthy, because reconstitution is chemistry, not pharmacology. Dissolving a known mass of peptide in a known volume of bacteriostatic water produces a known concentration, full stop. What that concentration means for a research protocol is a separate, uncertain question — but the arithmetic itself is exact and worth mastering, because a concentration error is the most common and most avoidable mistake in the entire workflow.

The core equation

The only formula you need is:

Concentration (mg/mL) = peptide mass (mg) ÷ diluent volume (mL).

For a 10mg vial:

10 mg ÷ 1 mL bacteriostatic water = 10 mg/mL (equivalent to a 1% Semax-style solution, or 10,000 mcg/mL)

10 mg ÷ 2 mL = 5 mg/mL (5,000 mcg/mL)

10 mg ÷ 2.5 mL = 4 mg/mL (4,000 mcg/mL)

10 mg ÷ 5 mL = 2 mg/mL (2,000 mcg/mL)

10 mg ÷ 10 mL = 1 mg/mL (equivalent to a 0.1% Semax-style solution, or 1,000 mcg/mL)

Notice how the two Semax reference solutions fall naturally out of this table: reconstituting the 10mg vial with 1 mL gives you the 1% (10 mg/mL) anchor, and with 10 mL gives you the 0.1% (1 mg/mL) anchor. That is the cleanest way to relate an Adamax vial to the only real concentration standards in the family. For a deeper walk-through of diluent choice and sterile technique, our guide to how much bacteriostatic water to use in peptide reconstitution covers the practical variables, and the interactive peptide dosage calculator will run these conversions for any vial size and volume you enter.

Converting concentration into insulin-syringe units

Research handling of small peptide volumes almost always uses a U-100 insulin syringe, where the barrel is graduated so that 100 units = 1 mL, meaning 1 unit = 0.01 mL. The mcg drawn per unit is simply the concentration in mcg/mL multiplied by 0.01. Worked example at 10 mg/mL (the 1 mL reconstitution): 10,000 mcg/mL × 0.01 mL = 100 mcg per unit. So on that dilution, 3 units on the syringe corresponds to 300 mcg, and 6 units to 600 mcg — numbers offered here purely to show the conversion, not as a recommended amount.

The table below is the practical heart of this article: it maps the 10mg Adamax vial across common bacteriostatic-water volumes to concentration, to mcg per insulin unit (U-100), and — because this family is so associated with intranasal use — to mcg per typical nasal-spray metered actuation (modeled at 0.05 mL, which is a common spray-pump volume; real pumps vary and must be measured).

1 mL

10 mg/mL

10,000

100 mcg

500 mcg

1% solution

2 mL

5 mg/mL

5,000

50 mcg

250 mcg

0.5%

2.5 mL

4 mg/mL

4,000

40 mcg

200 mcg

0.4%

5 mL

2 mg/mL

2,000

20 mcg

0.2%

10 mL

1 mg/mL

1,000

10 mcg

0.1% solution

A crucial interpretive caveat sits underneath this tidy table: a mathematically derivable “unit” or “per-actuation” figure is not an endorsement of any dose. The table tells you what is in a given volume at a given dilution; it says nothing about what quantity is appropriate, safe, or effective, because for Adamax that has never been established. The math is a measurement tool, not a protocol.

Working the arithmetic backwards from a target amount

Researchers modeling a specific quantity usually run the calculation in reverse: they start from a target mass and solve for the volume to draw. The rearranged formula is volume to draw (mL) = target amount (mcg) ÷ concentration (mcg/mL), and to express that in insulin units you multiply the resulting mL by 100. Take a worked example at the 5 mg/mL dilution (10mg vial in 2 mL), which is 5,000 mcg/mL. To model 250 mcg: 250 ÷ 5,000 = 0.05 mL, and 0.05 × 100 = 5 units on the syringe. To model 100 mcg on that same dilution: 100 ÷ 5,000 = 0.02 mL = 2 units. The virtue of the reverse calculation is that it forces the concentration into the open, which is exactly where errors hide — a “250 mcg” instruction is meaningless until you state the mg/mL it is being drawn from, because 250 mcg is 5 units at 5 mg/mL but only 2.5 units at 10 mg/mL. These worked numbers are arithmetic demonstrations, offered to make the conversion transparent, not recommendations of any amount.

The most common reconstitution errors

Three mistakes account for most of the concentration disasters seen in this space, and all three are avoidable with the formula above. First, conflating the vial total with a dose: treating “10 mg” as if it were a single administration rather than the entire container’s contents. Second, ignoring concentration entirely: quoting a mcg figure with no mg/mL behind it, which makes the number undrawable and untranslatable to syringe units. Third, unit confusion on the syringe: mixing up the “units” marked on a U-100 insulin syringe (a volume marking, where 100 units = 1 mL) with micrograms of peptide (a mass), which are related only through the concentration you chose at reconstitution. A researcher who internalizes that units are volume and micrograms are mass — and that only the concentration connects them — will avoid nearly every arithmetic trap. When in doubt, entering the vial size and diluent volume into the peptide dosage calculator cross-checks the hand arithmetic instantly.

A note on nasal delivery volume and total-dose accounting

Intranasal work adds a second arithmetic layer that trips people up. The nose can only comfortably hold a small liquid volume per nostril (often cited around 0.1–0.15 mL before runoff), so a higher concentration is usually preferred over a larger volume when a larger amount is being modeled. This is precisely why the Russian Semax products are sold at 0.1% and 1% rather than as huge dilute volumes: concentration lets a meaningful mass fit in a nose-friendly drop. If a protocol contemplates delivering, say, 250 mcg intranasally, the 5 mg/mL dilution places that in 0.05 mL — a realistic single actuation — whereas the 1 mg/mL dilution would require 0.25 mL, likely split across multiple drops or nostrils. Again, these are modeling mechanics, not dosing advice.

Adamax Dosage Figures: Literature vs Community

Here is the section the keyword demands and where honesty matters most. There are two entirely different kinds of “adamax dosage” numbers floating around, and conflating them is the central error this article exists to prevent.

What the literature actually contains (parent-compound only)

The literature contains dosing figures for Semax, Selank and ACTH(4-10) — not for Adamax. In Russian clinical use, Semax nasal solution for ischemic stroke has been administered at roughly 6,000–18,000 mcg per day (6–18 mg), with one non-randomized post-stroke study using 6,000 mcg/day intranasally delivered as two ten-day courses and reporting increases in plasma BDNF alongside functional-scale improvements.[7] Preclinical neuroprotection work in rodents commonly used 50–250 µg/kg intranasally.[2] Selank’s anxiolytic trial used 1,350 mcg/day.[15] Every one of these is a parent-compound figure, generated in a defined population, at a defined concentration, for a defined indication that has no bearing on any individual’s situation and is not transferable to Adamax as though it were an Adamax result.

What the community circulates (unvalidated)

Separately, peptide forums and vendor pages circulate Adamax “doses” — often in the low hundreds of micrograms intranasally, sometimes framed around the same 250–600 mcg band that community Semax lore uses. These figures have no published Adamax study behind them. They are, at best, someone’s extrapolation from the Semax 0.1%/1% solutions and community habit; at worst they are copied without any concentration accounting at all. This site’s own Adamax protocol page presents circulated figures for completeness, and we say plainly here what we say there: those numbers are unvalidated modeling references, not evidence-based doses.

The correct mental model is a hierarchy of confidence. Reconstitution math: fully reliable. Parent-compound Semax/Selank/ACTH(4-10) dosing: real but not about Adamax and not clinical guidance for anyone. Adamax-specific community doses: unvalidated folklore. A dosage reference earns trust by keeping these tiers visibly separate rather than blending them into a single confident-sounding recommendation.

Semax ischemic-stroke clinical use (Russia)

6,000–18,000 mcg/day intranasal[7]

Non-randomized clinical (parent compound)

No — different compound, clinical indication

Semax rodent neuroprotection

50–250 µg/kg intranasal[2]

Preclinical/animal (parent compound)

No — animal, not Adamax

Selank anxiolytic trial

1,350 mcg/day intranasal[15]

Small clinical (different peptide)

No — different peptide entirely

Community Adamax lore

~250–600 mcg intranasal

Anecdotal / unvalidated

No published basis of any kind

Adamax vs Semax Dosing: What the Concentration Anchors Actually Mean

Because “adamax vs semax dosing” is one of the most common comparison searches, it deserves a dedicated, careful treatment — and the careful answer is that the only rigorous thing shared between them is the concentration framework, not a validated dose equivalence. If, and only if, a particular Adamax product is confirmed to be the same molecule as Semax (same sequence, same molecular weight of roughly 813.9 g/mol for Met-Glu-His-Phe-Pro-Gly-Pro), then the Semax concentration anchors apply directly: a 10mg vial in 1 mL is a 1% solution, in 10 mL is a 0.1% solution, and the mcg-per-unit table above holds without modification.

If the Adamax product is a different ACTH(4-10) analog — a different sequence or a modified structure — then even the molecular weight can differ, and a milligram of Adamax may not contain the same molar quantity of active peptide as a milligram of Semax. In that case, transferring a Semax micrograms figure onto Adamax is not just uncertain, it can be quantitatively wrong at the level of moles. This is why we keep returning to the sequence-confirmation problem: without a certificate of analysis establishing identity and purity, “adamax vs semax dosing” cannot be resolved beyond the shared arithmetic scaffold.

Practical implications of the comparison

The productive way to use the Semax comparison is as a modeling boundary, not a prescription. The Semax literature establishes the concentration range at which this chemical family has been studied at all — roughly the 0.1% to 1% window for intranasal solutions, and micrograms-to-low-milligrams total daily amounts in human clinical settings. That window is context for laboratory modeling: it tells a researcher what order of magnitude the parent compound was used at, which is genuinely more informative than a random forum number. It does not tell that researcher what Adamax does, whether Adamax shares Semax’s therapeutic window, or that any of these amounts is appropriate for any purpose. The comparison narrows the uncertainty; it does not eliminate it.

There is also a units subtlety worth flagging for anyone converting between the two. Because Semax has a known molecular weight (about 813.9 g/mol), a stated milligram amount corresponds to a specific molar quantity, and the intranasal solution strengths (0.1% and 1%) map onto the mg/mL anchors used throughout this article. If an Adamax product is a heavier or lighter analog, the same milligram mass contains fewer or more moles of peptide, so two products delivering “the same mcg” are not necessarily delivering the same number of molecules to the target. For a family whose activity is receptor- and transcription-mediated, molecules — not milligrams — are the currency that matters. This is a further reason that “adamax vs semax dosing” cannot be answered as a simple mcg-for-mcg swap without confirming molecular identity, and why the certificate of analysis is not a bureaucratic nicety but the gate to any honest comparison.

It is also worth stating that even within the Semax literature the dose–response relationship is not cleanly established for cognition in healthy subjects — the human ACTH(4-10) attention work is old, small, and produced inconsistent, sometimes negative results.[12] So the parent compound itself does not offer a crisp “optimal dose,” which makes any claim of a crisp optimal Adamax dose doubly unsupportable.

Intranasal vs Subcutaneous: Route Considerations in Adamax Research

The phrase “adamax intranasal research” reflects the reality that the entire Semax family is overwhelmingly an intranasal story. There are concrete pharmacological reasons for this, and they bear directly on how any dosage would be modeled.

Why intranasal dominates the parent literature

Peptides in this family are cleared from plasma extremely rapidly — Semax’s intact molecule is short-lived systemically before enzymatic cleavage, with the Pro-Gly-Pro fragment quickly coming to predominate in biological samples.[10][11] Intranasal delivery is favored partly because it exploits nose-to-brain transport pathways that may allow a fraction of the peptide to reach the central nervous system while bypassing some first-pass degradation, and pharmacokinetic work in rats has specifically characterized Semax penetration into brain and blood after intranasal administration.[10] Practically, this is why Russian Semax is a nasal solution and why community protocols for the whole family default to drops or sprays. It is the route with the most supporting data.

Where subcutaneous fits (and where it does not)

Some community protocols and this site’s dosage tooling also discuss subcutaneous reconstitution, largely because the insulin-syringe mcg-per-unit math is identical regardless of route — the concentration table above applies to a subcutaneous draw exactly as it does to loading a nasal dropper. However, the evidence for subcutaneous administration of these specific peptides is thinner than for intranasal, and the nose-to-brain rationale that motivates the family does not straightforwardly carry over to a subcutaneous depot. In other words, the arithmetic transfers cleanly across routes but the pharmacological justification does not. Anyone comparing routes should treat the subcutaneous figures as a pure concentration exercise, not as a route with its own Adamax evidence.

Two further route-linked variables complicate any dosing model and deserve explicit mention. The first is bioavailability: intranasal delivery does not put 100% of the loaded mass into the target compartment — a portion drains, is swallowed, or is degraded at the mucosa — so the “mcg per actuation” figure in the reconstitution table is the amount presented, not the amount absorbed centrally. The absorbed fraction for these peptides is not precisely characterized for Adamax and is itself variable in the parent literature. The second is inter-device variability: two nasal pumps rated for different metered volumes will deliver different masses from the identical solution, which is why the table models a generic 0.05 mL actuation and why any serious protocol measures its actual pump output rather than trusting the rating. Both variables mean the gap between a calculated number and a delivered quantity is wider intranasally than it is for a subcutaneous draw, where the full drawn volume enters the depot.

Reconstitution differences by route

Route also nudges the preferred dilution. For intranasal modeling, a moderately high concentration (say 4–10 mg/mL) keeps the delivered volume within what a nostril tolerates. For subcutaneous modeling, more dilute solutions (2–5 mg/mL) make small amounts easier to measure accurately on an insulin syringe, since drawing 2 units is more precise than drawing a fraction of a unit. These are handling considerations, and they are legitimately useful; they still do not constitute a dose recommendation. Our bacteriostatic water reconstitution guide covers how measurement precision drives diluent choice.

What Is the Current Evidence Level for Adamax?

Stating the evidence tier precisely is a compliance and honesty requirement, so here it is without hedging. Adamax is a research chemical that is not approved by any regulatory authority — not the FDA, not the EMA, not (as a distinct product) even the Russian registries that cover Semax and Selank. There is no pharmacopoeial monograph for Adamax, no approved indication, and no published human or animal study that investigates “Adamax” under that name with a defined structure.

The evidence that does exist belongs to the parent compounds and must be tiered honestly:

Semax: registered in Russia (a national approval, not FDA/EMA) for ischemic stroke and related indications, supported mainly by Russian clinical studies that are frequently non-randomized, open-label, or small, plus a substantial preclinical literature.[7][6] Independent Western replication at modern trial standards is largely absent.[8]

Selank: registered in Russia as an anxiolytic; principal clinical support is a small comparative trial versus a benzodiazepine.[15]

ACTH(4-10): historical human research on attention and memory, investigational and never approved, with inconsistent findings.[13]

Adamax: preclinical-by-analogy at best; in reality, no direct evidence at all.

It is worth being candid about the quality of the parent evidence too, because “registered in Russia” can sound more authoritative than the underlying trials warrant. Much of the Semax clinical record consists of open-label or non-randomized designs, modest sample sizes, single-center Russian settings, and outcome measures that are not always blinded — features that, by contemporary evidence-based-medicine standards, place the findings well below the bar of a large multicenter randomized controlled trial.[7] The preclinical work is more mechanistically detailed but is animal and in-vitro data, which never translates one-to-one to human dosing. This is not a dismissal of the parent literature — it is a genuinely interesting body of neuropeptide research — but a dosage reference has to grade it honestly rather than let a national registration masquerade as definitive proof. When the best-supported member of the family sits at this evidence tier, the unstudied member (Adamax) cannot logically sit higher.

The single most important sentence in this article is this: no amount of Semax evidence upgrades Adamax from “research chemical with no direct data” to anything higher. Borrowing a parent-compound’s registration or trial as if it validated Adamax would be exactly the preclinical-to-clinical inflation the honesty rules forbid.

Stability, Storage, and Handling in Research Settings

Even though these are handling rather than dosing questions, they materially affect the integrity of any concentration you calculate, so they belong in a serious dosage reference. Lyophilized peptides in this family are generally most stable as the dry powder and are typically stored cold; once reconstituted, an aqueous peptide solution is far more vulnerable to degradation over time.

Before reconstitution

The freeze-dried 10mg powder should be kept per the supplier’s specification — commonly refrigerated for shorter-term storage and frozen for longer-term, protected from light and moisture. A vial that has been shipped warm, or that shows melted/collapsed cake, is a candidate for degradation, and any concentration you calculate from it assumes the labeled 10 mg is intact peptide. Purity and identity ultimately come from a certificate of analysis, not from the label alone — a point that matters even more for a compound like Adamax whose sequence may not be independently verifiable.

After reconstitution

Once bacteriostatic water is added, the benzyl alcohol it contains provides bacteriostatic (not sterilizing) protection and allows multi-draw use over a limited window, but the peptide itself still degrades in solution. Reconstituted solutions are generally refrigerated, kept out of light, not frozen-thawed repeatedly, and used within a bounded period. This is one more reason the reconstitution math is not merely academic: if you dilute the whole 10mg vial into 10 mL and only model small amounts, you are committing to a large volume of solution whose concentration integrity you must maintain for the life of the vial. Choosing a dilution is partly a stability decision, not only a concentration decision. A pragmatic corollary is that heavily diluting the entire vial for the sake of easy small-volume measurement can backfire: the larger the aqueous volume you create, the longer that solution must remain chemically intact before it is used up, and peptide in water does not wait indefinitely. Some researchers therefore reconstitute more concentrated and accept slightly less measurement headroom, precisely to shrink the standing volume and the time-at-risk. There is no single correct answer — only a trade-off between measurement precision and solution longevity that each protocol resolves for itself. The peptide reconstitution guide and the peptide research glossary expand on these handling terms.

Limitations, Unknowns, and Red Flags

A dosage article that did not foreground its own limits would be failing the reader. The limitations here are unusually severe and worth enumerating.

No Adamax-specific data of any kind. The foundational limitation is that there is no published Adamax pharmacology, toxicology, pharmacokinetics, or dose-ranging. Everything substantive in this article about mechanism and dosing is parent-compound inference, explicitly labelled as such.

Identity ambiguity. “Adamax” is a market name, not a defined chemical entity in the scientific literature. Two vendors’ Adamax could differ. Without a sequence and molecular-weight confirmation from a certificate of analysis, even the reconstitution math — while arithmetically correct — rests on the assumption that the vial contains 10 mg of the peptide you think it does.

Parent evidence is itself limited. The Semax and Selank clinical literature is predominantly Russian, often non-randomized, frequently small, and not independently replicated to Western regulatory standards.[8] The historical ACTH(4-10) human cognition work is old and inconsistent.[12] So even the compounds Adamax leans on do not offer a clean, high-confidence dosing standard.

No safety dataset. There is no characterized adverse-event profile, contraindication list, or interaction data for Adamax specifically. Absence of reported harm is not evidence of safety; it is evidence of absence of study. A compound can be poorly characterized and still carry real risks that simply have not been measured or reported, and the quiet of an unstudied safety record should be read as ignorance, not reassurance.

Route and formulation variability. Nasal-spray actuation volumes vary between devices, so the “mcg per actuation” column in the reconstitution table is a model, not a measurement of any specific pump. Real delivered volume must be measured, not assumed.

Red flags to treat skeptically. Any source presenting a confident, specific Adamax dose as though it were validated; any protocol that omits concentration accounting entirely (a “dose” in mcg is meaningless without a mg/mL to draw it from); and any claim that Adamax “treats,” “cures,” or reliably produces a named outcome — none of which the evidence supports. For researchers interested in adjacent short-peptide families and how evidence quality is assessed across them, the internal library includes deeper explainers reached from the linked pages above.

Frequently Asked Questions

Is there an official Adamax dosage?

No. There is no official, approved, or clinically established Adamax dosage anywhere, because Adamax has never been the subject of a published dose-ranging study and is not approved by any regulatory authority. Every circulating “adamax dosage” figure is extrapolated from the parent Semax and ACTH(4-10) literature or from community lore. Those figures are unvalidated modeling references for laboratory work, not guidance for use in a person.

How do you reconstitute a 10mg Adamax vial?

Reconstitution is straightforward arithmetic: concentration equals mass divided by volume. Adding 1 mL of bacteriostatic water to a 10mg vial gives 10 mg/mL; adding 2 mL gives 5 mg/mL; adding 5 mL gives 2 mg/mL; adding 10 mL gives 1 mg/mL. These correspond to the Semax-style 1% and 0.1% solution anchors at the extremes. The math is reliable; what it does not tell you is what amount is appropriate, because that has never been established for Adamax.

How does Adamax dosing compare to Semax dosing?

The only rigorously shared element is the concentration framework, not a validated dose. If a specific Adamax product is confirmed to be the same molecule as Semax (same sequence and molecular weight), the Semax concentration anchors and the mcg-per-unit table transfer directly. If it is a different ACTH(4-10) analog, even the molecular weight may differ, so a Semax micrograms figure could be quantitatively wrong for Adamax. Confirming identity via a certificate of analysis is the prerequisite for any comparison.

What does the 10mg on the vial actually mean?

It is the total mass of lyophilized peptide in the container — not a per-administration amount. From 10 mg you can make many working concentrations depending on how much bacteriostatic water you add. Confusing this total with a “dose” is the single most common error in the space. The 10mg figure is the one hard fact; everything else is a dilution decision layered on top of it.

Why is almost everything here about Semax instead of Adamax?

Because that is where the citable evidence lives. Adamax is marketed as a member of the Semax/ACTH(4-10) neuropeptide family but has no published studies of its own. Responsible reporting means describing the parent-compound pharmacology transparently and labelling it as parent-compound data, rather than inventing Adamax-specific studies that do not exist. Any article claiming direct Adamax trials would be fabricating them.

Is Adamax approved by the FDA?

No. Adamax is not approved by the FDA or the EMA, and even as a distinct product it is not covered by the Russian registrations that apply to Semax and Selank. It is a research chemical with no approved indication and no pharmacopoeial monograph. The parent compound Semax carries a Russian national registration for ischemic stroke, but that approval does not extend to Adamax and is not an FDA or EMA approval.

What is the difference between intranasal and subcutaneous reconstitution?

The mcg-per-unit arithmetic is identical for both routes because it depends only on concentration. The differences are practical: intranasal modeling favors higher concentrations (roughly 4–10 mg/mL) so a meaningful amount fits in a nose-tolerable volume, while subcutaneous modeling often uses more dilute solutions (2–5 mg/mL) for measurement precision on an insulin syringe. The parent literature is overwhelmingly intranasal, and the nose-to-brain rationale does not straightforwardly transfer to subcutaneous delivery.

How stable is a reconstituted Adamax solution?

Once reconstituted, aqueous peptide solutions degrade over time and are generally refrigerated, protected from light, and used within a bounded window; the benzyl alcohol in bacteriostatic water provides bacteriostatic, not sterilizing, protection. The dry lyophilized powder is more stable and is typically stored cold or frozen. Because dilution commits you to maintaining a given volume of solution for the life of the vial, choosing a concentration is partly a stability decision, not only a dosing-math decision.

Can I use the parent-compound doses as my Adamax protocol?

No. Parent-compound figures such as Semax stroke doses (6,000–18,000 mcg/day) or Selank’s 1,350 mcg/day were generated in specific clinical populations for specific indications with different molecules, and they are neither transferable to Adamax nor guidance for any individual. They are useful only as context for the order of magnitude at which this chemical family has been studied, and strictly for research modeling, never as a personal protocol.

References

Dolotov OV, et al. Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. 2006. PubMed 16635254. onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2006.03658.x

Dolotov OV, et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006. PubMed 16996037. sciencedirect.com/science/article/abs/pii/S0006899306022955

Eremin KO, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research. 2005. PubMed 16362768. link.springer.com/article/10.1007/s11064-005-8826-8

Medvedeva EV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014. ncbi.nlm.nih.gov/pmc/articles/PMC3987924

Sudarkina OY, et al. Brain protein expression profile confirms the protective effect of the ACTH(4–7)PGP peptide (Semax) in a rat model of cerebral ischemia–reperfusion. International Journal of Molecular Sciences. 2021. ncbi.nlm.nih.gov/pmc/articles/PMC8226508

Dmitrieva VG, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology. 2009. pmc.ncbi.nlm.nih.gov/articles/PMC11498467

Gusev EI, Martynov MY, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii. 2018. PubMed 29798983. pubmed.ncbi.nlm.nih.gov/29798983

Dergunova LV, et al. Neuroprotective peptides and new strategies for ischemic stroke drug discoveries. Genes. 2023. pmc.ncbi.nlm.nih.gov/articles/PMC10218113

Kolbaev SN, et al. The effect of peptide Semax, an ACTH(4-10) analogue, on intracellular calcium dynamics in rat brain neurons. Bulletin of Experimental Biology and Medicine. 2025. PubMed 41171324. link.springer.com/article/10.1007/s10517-025-06501-z

Shevchenko KV, et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Russian Journal of Bioorganic Chemistry. 2006. PubMed 16523722. link.springer.com/article/10.1134/s1068162006010055

Dolotov OV, et al. The binding of Semax, an ACTH(4-10) heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation. 2004. PubMed 15344653. pubmed.ncbi.nlm.nih.gov/15344653

Born J, et al. Dose-dependent influences on electrophysiological signs of attention in humans after neuropeptide ACTH 4–10. Experimental Brain Research. 1987. PubMed 3040455. link.springer.com/article/10.1007/BF00269456

Smolnik R, Born J, et al. Event-related brain potentials and working memory function in healthy humans after single-dose and prolonged intranasal administration of adrenocorticotropin 4-10 and desacetyl-alpha-melanocyte stimulating hormone. Journal of Clinical Psychopharmacology. 2000. PubMed 10917406. pubmed.ncbi.nlm.nih.gov/10917406

Filippenkov IB, et al. Insight into glyproline peptides’ activity through the modulation of the inflammatory and neurosignaling genetic response following cerebral ischemia–reperfusion. Genes. 2022. PubMed 36553646. ncbi.nlm.nih.gov/pmc/articles/PMC9777888

Zozulya AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. 2008. PubMed 18454096. pubmed.ncbi.nlm.nih.gov/18454096

Research-use-only disclaimer: This article is an educational research reference, not medical advice. Adamax is a research chemical that is not approved for human use by any regulatory authority, and nothing here is a recommendation to administer any substance to a person or animal. Every dosage figure discussed is drawn from parent-compound (Semax, Selank, ACTH(4-10)) literature or unvalidated community reports and is presented solely for laboratory research modeling; none has been validated for Adamax. The reconstitution arithmetic is provided to illustrate concentration mathematics, not to endorse any dose. Always consult a qualified professional and comply with all applicable laws and institutional guidelines.